Professor Sydney Tang, MBBS, MD, PhD

Chairman, Institutional Review Board, The University of Hong Kong / Hospital Authority Hong Kong West Cluster

Clinical Professor, Department of Medicine, The University of Hong Kong

Member, Hospital Governing Committee, Grantham Hospital, Hong Kong Hospital Authority

Member, Central Renal Committee, Hong Kong Hospital Authority

Chairman, Basic Physician Board, Hong Kong College of Physicians

Member, Specialty Board in Nephrology, Hong Kong College of Physicians

Member, Committee of Management, Clinical Trials Centre, The University of Hong Kong

Hong Kong, China
 
Biography:
 
Sydney Tang graduated from the University of Hong Kong and has obtained MD and PhD degrees at HKU. He has undergone training in basic science research in nephrology at Guy’s Hospital, King’s College London, and Seattle Children’s Hospital, University of Washington. He is currently Clinical Professor of Medicine and Yu Endowed Professor in Nephrology at The University of Hong Kong. His research interests range from basic to clinical sciences including the role of renal tubular cells in diabetic and proteinuric nephropathies, and the treatment of IgA nephropathy. He has numerous publications, and is on the Editorial Boards of Kidney International, Nephrology Dialysis Transplantation, American Journal of Nephrology, Nephrology, and Journal of Nephrology. He serves the Hong Kong Society of Nephrology as Honorary Secretary and the Asian Pacific Society of Nephrology (APSN) as Honorary Treasurer. He is also a Core member of the Committee for Kidney Health in Disadvantaged Populations (CKHDP) of the ISN Global Outreach Programme. He has been invited to deliver lectures at many national and international meetings including the American Society of Nephrology Kidney Week and the World Congress of Nephrology. He is also the Vice-President of the first International Congress of Chinese Nephrologists (ICCN) to be held in HK in Dec 2015.
 
Session:
 
21st November 2015 (Saturday) 13:25 – 13:50
 
Session III: Early Clinical Development in Asia
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong